Neurogene Inc (NGNE) - Total Assets
Based on the latest financial reports, Neurogene Inc (NGNE) holds total assets worth $263.14 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Neurogene Inc (NGNE) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Neurogene Inc - Total Assets Trend (2011–2025)
This chart illustrates how Neurogene Inc's total assets have evolved over time, based on quarterly financial data. See net assets of Neurogene Inc for net asset value and shareholders' equity analysis.
Neurogene Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Neurogene Inc's total assets of $263.14 Million consist of 94.2% current assets and 5.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 36.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Neurogene Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NGNE company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neurogene Inc's current assets represent 94.2% of total assets in 2025, a decrease from 96.0% in 2011.
- Cash Position: Cash and equivalents constituted 36.0% of total assets in 2025, down from 93.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2011.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Neurogene Inc Competitors by Total Assets
Key competitors of Neurogene Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Neurogene Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.08 | 21.03 | 22.09 |
| Quick Ratio | 13.08 | 21.03 | 22.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $227.88 Million | $282.30 Million | $159.91 Million |
Neurogene Inc - Advanced Valuation Insights
This section examines the relationship between Neurogene Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.96 |
| Latest Market Cap to Assets Ratio | 2.27 |
| Asset Growth Rate (YoY) | -14.0% |
| Total Assets | $288.60 Million |
| Market Capitalization | $656.17 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Neurogene Inc's assets at a significant premium (2.27x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Neurogene Inc's assets decreased by 14.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Neurogene Inc (2011–2025)
The table below shows the annual total assets of Neurogene Inc from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $288.60 Million | -14.04% |
| 2024-12-31 | $335.73 Million | +50.84% |
| 2023-12-31 | $222.57 Million | +103.70% |
| 2022-12-31 | $109.27 Million | +7.66% |
| 2021-12-31 | $101.49 Million | -51.79% |
| 2020-12-31 | $210.52 Million | +43.19% |
| 2019-12-31 | $147.02 Million | +89.42% |
| 2018-12-31 | $77.62 Million | -29.65% |
| 2017-12-31 | $110.33 Million | -28.53% |
| 2016-12-31 | $154.38 Million | +36.21% |
| 2015-12-31 | $113.34 Million | +173.62% |
| 2014-12-31 | $41.42 Million | -29.52% |
| 2013-12-31 | $58.77 Million | +2409.35% |
| 2012-12-31 | $2.34 Million | -76.31% |
| 2011-12-31 | $9.88 Million | -- |
About Neurogene Inc
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disea… Read more